

Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins[§]

Caroline Subra,^{*,§} David Grand,^{**} Karine Laulagnier,^{††} Alexandre Stella,^{§§} Gérard Lambeau,^{***} Michael Paillasse,^{*,§} Philippe De Medina,^{*,§} Bernard Monsarrat,^{§§} Bertrand Perret,[†] Sandrine Silvente-Poirot,^{*,§} Marc Poirot,^{*,§} and Michel Record^{1,*,§}

Metabolism, Oncogenesis and Cell Differentiation Group* and Lipoproteins, Lipid Transport and Dislipidemia Group,[†] INSERM Research Center 563, Pathophysiology Center of Toulouse Purpan (CPTP), Hôpital Purpan, Toulouse, France; Paul Sabatier University (UPS),[§] Toulouse, France; Anatomopathology and Cytology Service,^{**} Hôpital Purpan, Toulouse, France; Biochemistry Department,^{††} University of Sciences II, Geneva, Switzerland; Institute of Pharmacology and Structural Biology (IPBS),^{§§} CNRS, Toulouse, France; and Institute of Molecular and Cellular Pharmacology,^{***} CNRS, Sophia-Antipolis University, Valbonne, France

Abstract Exosomes are bioactive vesicles released from multivesicular bodies (MVB) by intact cells and participate in intercellular signaling. We investigated the presence of lipid-related proteins and bioactive lipids in RBL-2H3 exosomes. Besides a phospholipid scramblase and a fatty acid binding protein, the exosomes contained the whole set of phospholipases (A2, C, and D) together with interacting proteins such as aldolase A and Hsp 70. They also contained the phospholipase D (PLD) / phosphatidate phosphatase 1 (PAP1) pathway leading to the formation of diglycerides. RBL-2H3 exosomes also carried members of the three phospholipase A2 classes: the calcium-dependent cPLA₂-IVA, the calcium-independent iPLA₂-VIA, and the secreted sPLA₂-IIA and V. Remarkably, almost all members of the Ras GTPase superfamily were present, and incubation of exosomes with GTPγS triggered activation of phospholipase A₂ (PLA₂) and PLD₂. A large panel of free fatty acids, including arachidonic acid (AA) and derivatives such as prostaglandin E₂ (PGE₂) and 15-deoxy-Δ^{12,14}-prostaglandinJ₂ (15-d PGJ₂), were detected. We observed that the exosomes were internalized by resting and activated RBL cells and that they accumulated in an endosomal compartment. Endosomal concentrations were in the micromolar range for prostaglandins; i.e., concentrations able to trigger prostaglandin-dependent biological responses. Therefore exosomes are carriers of GTP-activatable phospholipases and lipid mediators from cell to cell.—Subra, C., D. Grand, K. Laulagnier, A. Stella, G. Lambeau, M. Paillasse, P. De Medina, B. Monsarrat, B. Perret, S. Silvente-Poirot, M. Poirot, and M. Record. **Exosomes account for vesicle-mediated transcel-**

ular transport of activatable phospholipases and prostaglandins. *J. Lipid Res.* 2010. 51: 2105–2120.

Supplementary key words exosome • phosphatidate phosphatase • arachidonic acid • docosahexaenoic acid • prostaglandin

Exosomes are nanovesicles (50–100 nm) released from viable cells, either constitutively or upon activation of cell secretion, but not from lysed or apoptotic cells (1). They are secreted from an intracellular compartment, the multivesicular bodies (MVB), or late endosomes (2). The “TfR/tetraspanin/Heat-Shock Protein”-containing exosomes originating from MVB differ from the “CD73 (5′-nucleotidase)/glycophorin/CD45”-containing microvesicles produced by plasma membrane shedding (3) and from “CD31/Annexin V”-containing apoptotic microparticles (4).

Exosomes were first characterized as a pathway for elimination of obsolete proteins during erythrocyte maturation.

Abbreviations: 15-d PGJ₂, 15-deoxy-Δ^{12,14}-prostaglandinJ₂; AA, arachidonic acid; BEL, bromo-eno-lactone; DG, diglycerides; DHA, docosahexaenoic acid; FABP, fatty acid binding protein; LPC, lysophosphatidylcholine; MAFP, methyl arachidonyl fluorophosphonate; Me-indoxam, methyl-indoxam; MVB, multivesicular bodies; PA, phosphatidic acid; PAP, phosphatidate phosphatase; PC, phosphatidylcholine; PEt, phosphatidylethanol; PGE₂, prostaglandin E₂; PGF₂α, prostaglandin F₂α; PLA₂, phospholipase A₂; PLC, phospholipase C; PLD₂, phospholipase D₂; PPAR, peroxisome proliferator activated receptor; Rh-PE, rhodamine-phosphatidylethanolamine.

¹To whom correspondence should be addressed.

e-mail: michel.record@inserm.fr

[§]The online version of this article (available at <http://www.jlr.org>) contains supplementary data in the form of two figures.

This work was supported in part by funding from Agence Nationale pour la Recherche contre le SIDA (ANRS) (C.S.) and by internal grants from INSERM.

Manuscript received 30 October 2009 and in revised form 27 April 2010.

Published, JLR Papers in Press, April 27, 2010

DOI 10.1194/jlr.M003657

Copyright © 2010 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at <http://www.jlr.org>

tion, then as part of an essential process in the immune response, and recently as an enabler of the mechanism that modulates the translational activity of target cells by transferring selected micro RNA between cells (5). Whether exosomes participate dynamically in lipid metabolism is not known.

Exosomes appear to be involved in additional intercellular signaling beside soluble agonists. They interact with cell peripheral receptors, such as CD91 (6), a member of the LDL receptor-related proteins (LRP) receptors, and Tim4 (7), the phosphatidylserine receptor (8), a G protein coupled receptor (GPCR) member. Other nanovesicles similar to exosomes trigger the Notch signaling pathway (9).

The exosome biogenesis pathway can be "hijacked" by pathogens like the human immunodeficiency virus (HIV), by proteins like prions involved in Creutzfeldt-Jacob disease (10), and by the amyloid precursor protein (APP) of Alzheimer's disease (11, 12).

Mast cell-derived exosomes trigger functional maturation of dendritic cells (DC) (6). The DC maturation process has been shown to involve lysophosphatidylcholine and secreted PLA₂ (13), and prostaglandins (14). We previously reported that exosomes from RBL-2H3 cells contain a high amount of lysophosphatidylcholine (LPC) (15) and that phospholipase D was involved in exosome release (16).

We undertook a large analysis of RBL-2H3 exosome content by proteomic high-throughput analysis together with immunodetection and determination of lipolytic activities. We showed that exosomes can behave as "signalosomes" not only by transporting GTP-activatable phospholipases D₂ (PLD₂) and phospholipase A₂ (PLA₂), but also by carrying the whole set of prostaglandins, including prostaglandin E₂ (PGE₂) and the peroxisome proliferator activated receptor γ (PPAR γ) agonist 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ (15d-PGJ₂). We observed that exosomes could traffic between resting or activated RBL-2H3 cells, thereby modulating RBL-2H3 cell activation by means of the lipid messengers they carry. In addition, exosomes could constitute a mechanism of entry for 15d-PGJ₂, as the way this prostaglandin enters cells is as yet unknown (17–19).

EXPERIMENTAL PROCEDURES

Materials

For cell cultures, RPMI 1640, PBS, penicillin, streptomycin, L-glutamine, and FCS were purchased from Invitrogen. 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-PC as phospholipase substrate and BODIPY-ceramide for exosome labeling and uptake detection by immunofluorescence were obtained from Invitrogen Molecular Probes and stored in ethanol at -20°C after dilution. GTP γ S was from Sigma. Methyl arachidonyl fluorophosphate (MAFP) was from Calbiochem. Bromoenol lactone (BEL, or HaloEnol Lactone Suicide Substrate) was from Biomol International. Pyrrolidine-1 and Me-inoxam were generous gifts from Prof. M. H. Gelb (University of Washington, Seattle, WA). The cPLA₂ monoclonal antibody (recognizing type IVA) and iPLA₂ polyclonal antibody (recognizing type VIA) were from Santa Cruz Biotechnology. Mouse sPLA₂IIA and -V recombinant

proteins and sPLA₂ antibodies raised against type IIA and V sPLA₂ were produced as described (20). Polyclonal antibodies against cyclooxygenase (COX)-1 and COX-2 were from Santa Cruz Biotechnology. Rabbit polyclonal anti-PLD antibody (N-PLD4) was from Johnson Pharmaceutical Research Institute (Raritan, NJ) and was kindly supplied by Dr. D. Uhlinger. The HA.11 monoclonal mouse anti-HA antibody (clone 16B12) was from Eurogentec. Anti-CD63 antibody was from Santa Cruz Biotechnology. The anti-LBPA antibody (6C4) was kindly supplied by Dr. T. Kobayashi, Riken Institute, Tokyo, Japan (21). Secondary antibodies labeled with horseradish peroxidase were from Santa Cruz Biotechnology and PhycoErythrine-labeled antibodies from BD Bioscience. FITC-labeled cholera toxin subunit was from Sigma. Isotype antibodies for flow cytometry were from Santa Cruz Biotechnology. Rhodamine-phosphatidylethanolamine (Rh-PE) was from Avanti Polar Lipids (Birmingham, AL). Protease inhibitor cocktail (P8340) was provided by Sigma. Chemical solvents were purchased from Sigma-Aldrich or from Merck for HPLC grade.

Methods

Cell lines. RBL-2H3 (also referred to as RBLwt for RBL wild-type cells) were grown in RPMI 1640 supplemented with 10% (v/v) FCS, 4 mM L-glutamine, 140 units/ml penicillin, and 140 $\mu\text{g}/\text{ml}$ streptomycin in a 5% CO₂ humidified atmosphere at 37°C.

Cells overexpressing the human HA-tagged PLD₂ (also referred to as RBLpld2 cells) were obtained by electroporation (250 V, 500 μF) of RBL-2H3 cells with linearized pcDNA3.1 vector containing the HA-tagged cDNA of human PLD₂. PLD₂ overexpressing cells were selected with G418 (500 $\mu\text{g}/\text{ml}$). Clones grown within one week were recovered in PBS-EDTA, mixed, expanded, and stored in liquid nitrogen. The characteristics of the RBLpld2 cell line are reported in the supplemental data.

RBL cell degranulation. Cell secretion was monitored by the amount of ¹⁴C-serotonin released from the MVB compartment. Adherent cells were loaded overnight with ¹⁴C-serotonin, washed, and incubated for 4 h with saturating concentrations of IgE directed against dinitrophenol conjugated to serum albumin (DNP-HSA, Sigma). Cell activation was triggered by Fc ϵ RI cross-linking with DNP-has, and the radioactivity released was measured by scintillation counting.

Exosome preparation. For exosome preparation 1.5×10^7 adherent cells were harvested with PBS-EDTA and added into 250 ml complete RPMI medium in a spinner bottle for cell culture in suspension. Culture volume was doubled every day in the spinner bottles to maintain a cell density of around 0.25×10^6 cells/ml for good cell viability until about 10^9 cells were produced overall.

The cells were spun down, washed with DMEM medium, and concentrated to 10^8 cells in 10 ml of DMEM without FCS to avoid contamination by any microvesicles that might be present in the fetal calf serum. Exosomes were recovered following 20 min cell stimulation by ionomycin (1 μM final) and purified by differential centrifugations as reported previously (16). Correct exosome preparation required viable cells, which were checked by trypan blue exclusion. Briefly, viable activated cells were eliminated by centrifugation at 300 *g* for 5 min. To get rid of possible cell debris, the supernatant underwent two consecutive centrifugations at 2000 *g* for 20 min at 4°C and 10,000 *g* for 30 min at 4°C. Exosomes were isolated from the 10,000 *g* supernatant by ultracentrifugation at 110,000 *g* for 70 min at 4°C. The pellet was resuspended in PBS and centrifuged again at 110,000 *g* for 70 min at 4°C. The final pellet referred to as exosomes was resuspended in PBS for analysis. The quality of the preparations was checked by D₂O/sucrose discontinuous gradient (1) and by electron

microscopy (performed by D. Lankar, Institut Curie Paris; B. Payré, CMEAB, UPS Toulouse III, France). We also checked the size homogeneity of vesicles obtained using a Zetasizer Nano ZS90 (see below). Protein concentration was determined by the Lowry method (22) in the presence of 0.1% w/v SDS final.

Size distribution and zeta potential analysis of RBL-2H3-derived exosomes. The Zetasizer Nano ZS 90 (Malvern Instruments, Orsay, France), allowed the analysis of particles with sizes ranging from 1 nm to 3 μ m. Exosomes (50 μ g from two pooled preparations) derived from RBLwt or RBLpLd₂ cells were diluted in 1 ml PBS, and parameters such as zeta potential (electronegativity) and size distribution were analyzed at 37°C according to the manufacturer's instructions (see supplemental Fig. II).

Quantification of exosome vesicles. The correlation between exosome protein content and the number of vesicles was established by FACS analysis on the basis of the method used to quantify the number of circulating microparticles (4). Exosomes were diluted in PBS-EDTA and the number of vesicles was taken as the number of events in the SSC/FSC quadrant.

Quantification of exosome internalization. Exosomes were labeled with the fluorescent lipid probe BODIPY-ceramide so that fluorescence monitored the amount of vesicles directly (16). Fluorescent exosomes (25 μ g proteins) were incubated with 10⁶ adherent cells. At appropriate times, the excess of added exosomes removed, the cells washed, and cell-associated fluorescence monitoring internalized exosomes were extracted with butanol and quantified. The fluorescence was converted into μ g exosome protein using a calibration curve as previously reported (16).

Confocal microscopy. Internalization of fluorescent exosomes was monitored under a Zeiss LSM 510 confocal microscope on live cells using LSM 510 software. Cells (3×10^4 in RPMI medium buffered with 25 mM Hepes) were seeded in LabTek chambers and kept overnight in an incubator. Then medium was removed, and 0.5 ml of the same fresh medium was added. The LabTek chambers were placed into a microscope chamber adaptor warmed to 37°C and with CO₂ flow. Exosomes (20 μ g), previously made fluorescent by a 1 h incubation at 37°C with 1.2 μ M BODIPY-ceramide (23) and washed, were added in a small volume (20 μ l) into the cell medium and data acquisition started.

The compartment of exosome internalization in target cells was characterized by antibodies directed against late endosome markers. 2×10^5 cells were seeded on coverglass in 1 ml RPMI culture medium and incubated for 24 h with 75 μ l anti-LBPA antibody (hybridoma supernatant) or 50 μ l (10 μ g) anti-CD63 antibody. Cells were washed with PBS, then overlaid with 0.5 ml culture medium, and 10 μ g fluorescent (BODIPY-ceramide labeled) exosomes were added. Incubation proceeded for 4 h at 37°C. Cells were washed with PBS and fixed with 3.7% PFA for 20 min and washed again. The remaining PFA was quenched with 50 mM NH₄Cl for 10 min. The cells were washed with PBS, then maintained for 30 min in PBS 3% BSA. Permeabilization was performed with 0.05% saponin in PBS 3% BSA for 10 min. The cells were washed and incubated 30 min with appropriate secondary antibodies (anti-mouse PE for LBPA and anti-goat FITC for CD63). Coverslips were mounted with Mowiol, and samples were examined under a LSM 510 confocal microscope.

To label the late endosome compartment with Rhodamine-PE, cells were incubated in suspension at 4°C with 3 μ M final of the probe, washed with PBS 3% BSA, and incubated for an additional 3 h at 37°C. Cells were seeded on coverslips and pulsed for 4 h with fluorescent exosomes. After washing, cells were fixed with PFA and examined with the LSM 510.

Plasma membrane labeling was first performed on live RBLpLd₂ cells with fluorescent cholera toxin added in PBS containing 10% BSA at 4°C for 30 min. The cells were washed with PBS, fixed with 3% PFA for 20 min at 4°C, and permeabilized for 15 min at room temperature with 0.05% saponin in PBS-BSA. HA-PLD₂ location was then detected by incubation with anti-HA antibody diluted at 1/50, followed by incubation with a secondary antibody (45 min each antibody) at room temperature. Acquisition was performed with a Zeiss LSM 510 confocal microscope.

Measurement of phospholipase activities. Identification of the various phospholipase activities in exosomes was performed by HPLC using a fluorescent phosphatidylcholine (BODIPY-PC) as substrate. Intact or sonicated (2×10 s output 4-5 Micro Tip, Branson Sonifier) exosomes (50 μ g protein) were preincubated 10 min at room temperature in a total volume of 500 μ l PBS containing 2 mM Ca²⁺/Mg²⁺ with 5 μ l protease inhibitor cocktail, and as required 50 μ M PLA₂ inhibitors (MAFP for cPLA₂ > iPLA₂; pyrrolidine for cPLA₂; Me-indoxam for sPLA₂; BEL for iPLA₂). When calcium was not required, Ca²⁺/Mg²⁺ free-PBS was used. Concentrations of inhibitors and their specificity have already been documented (24, 25). When GTP dependency was checked, the nonhydrolysable analog of GTP (GTP γ S) was added 10 min before monitoring phospholipase activity. Substrate (1 μ l BODIPY-PC, 2.34 μ M final) was supplied in ethanol (0.2–2%v/v final). The reaction was performed for 1 h at 37°C. Fluorescent lipids were extracted with 2×500 μ l 1-n-butanol and were resolved by HPLC (see below).

Measurement of PA phosphatase activity. Fluorescent phosphatidic acid (BODIPY-PA) was prepared from BODIPY-PC by in vitro hydrolysis with commercial phospholipase D. For enzymatic PAP activity measurement, 50 μ g of exosomes were preincubated for 10 min at room temperature in a total volume of 500 μ l of PBS with 2 mM Ca²⁺/Mg²⁺, with or without 100 μ M GTP γ S, in the presence of 5 μ l protease inhibitor cocktail. The reaction was started by addition of 1 μ l BODIPY-PA (1 μ M final) supplied in ethanol and incubation proceeded at 37°C. Fluorescent lipids were extracted with 2×500 μ l 1-n-butanol and resolved by HPLC.

HPLC analysis. HPLC separation and quantification of BODIPY-PC-derived products were performed as already reported (26) on a silica diol column with a solvent flow rate of 0.4 ml/min. Fluorescent standards of lysophosphatidylcholine (LPC), phosphatidic acid (PA), diglycerides (DG) and phosphatidylethanol (PEt) were prepared by in vitro incubations of BODIPY-PC with appropriate lipolytic enzymes.

Calibration curves for quantification were plotted with BODIPY-PC as standard. HPLC peaks across chromatograms were identified by fluorescent standards injected in the middle of each series of samples to overcome variations in retention times.

Phospholipase immunodetection. For phospholipases A₂, cells and exosomes were lysed in Laemmli sample buffer at 95°C for 10 min and sonicated. 10 mM EDTA was added for phospholipase D detection. 40 μ g of proteins were run on 7.5% SDS-PAGE and transferred onto PVDF membrane. The membranes were saturated with 5% nonfat milk in TBS 0.1% Tween 20 for 1 h at room temperature and blotted at 4°C overnight with mouse or rabbit primary antibodies supplied in blotting buffer. Membranes were then washed and incubated in TBS 0.1% Tween 20 with HRP-labeled anti-mouse IgG or anti-rabbit IgG secondary antibodies for 1 h at room temperature.

For sPLA₂ detection, 40 μ g of exosome proteins were separated on a 15% SDS-polyacrylamide gel, compared to 50 ng of

group IIa and V recombinant sPLA₂ proteins as standards, and transferred onto PVDF membrane. Membranes were saturated in NETG buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.4, 0.05% Triton X-100, 0.25% gelatin), washed in PBS 0.05% Tween 20, and incubated in NETG buffer with HRP-labeled anti-rabbit IgG secondary antibodies.

In all cases, the signal was detected by the enhanced chemiluminescence system from GE Healthcare/Amersham.

Cyclooxygenase detection by flow cytometry. Exosomes (5 µg proteins) were bound on 4 µm beads (5 µl aldehyde sulfate latex beads; Invitrogen) for 1 h at room temperature under gentle shaking. Unoccupied sites were saturated with vesicle-free FCS for 1 h at room temperature. Beads were spun down, washed with PBS, and resuspended in FACS buffer. Bound exosomes were incubated with anti-COX-1 or anti-COX-2 primary antibodies, or control isotype for 1 h at room temperature and spun down, then labeled for 30 min with secondary FITC-labeled antibody. COX expression was analyzed by flow cytometry on the FITC channel (FL-1) of a FACSCalibur analyzer (Becton-Dickinson) using settings previously reported (16).

Protein analysis. High-throughput protein analysis was performed on 100 µg protein of purified exosome, first separated by one-dimensional SDS-PAGE. The protein gel lane was cut into 16 pieces, which were digested by trypsin. Tryptic peptides were analyzed by nanoLC-MS-MS with a Qstar XL spectrometer (Applied Biosystems). Data were searched against mouse entries in Sprot-Trembl with the Mascot software. Analyses were performed at the IPBS, CNRS, Toulouse, France (27).

Lipid analysis. Determination of free fatty acids in exosomes was performed at the lipidomics facility of IFR-BMT (Institut Fédératif de Recherche Bio-Médicale de Toulouse), Toulouse, France. RBL-2H3 derived exosomes (100 µg) were incubated in PBS with 2 mM Ca²⁺/Mg²⁺ at 37°C for 4 h. The lipids were extracted by the Bligh and Dyer method (28) in the presence of EGTA in water. Fatty acids were methylated and further analyzed by gas chromatography with an HP5890 instrument (29).

Prostaglandins were quantified by GC-MS at the lipidomics facility of IMBL/INSA-Lyon, Villeurbanne, France. Lipids from RBL-2H3 derived exosomes (70 µg) were extracted with ethylacetate, derivatized into pentafluorobenzyl esters, purified by silica gel TLC using chloroform/ethanol (93:7, v/v), and then modified into trimethylsilyl ethers before analysis by GC-MS. Samples were spiked with 10 ng of deuterated prostaglandin standards (Cayman) and GC-MS was carried out with a Hewlett Packard quadrupole mass spectrometer interfaced with a Hewlett Packard gas chromatograph (30).

Data presentation. HPLC profiles and phospholipase determinations representative of at least two independent experiments were plotted. Pooled exosome preparations from two to three experiments were used for protein and lipid analysis, which fulfilled the quality control stipulations of the respective facilities (IPBS and IFR-BMT, Toulouse, France; IMBL/INSA-Lyon, Villeurbanne, France). Confocal pictures were representative of at least two experiments performed by distinct operators. Error bars corresponded to SEM from three determinations.

RESULTS

Lipid-related proteins in exosomes

To determine which of the diverse lipid-related proteins were present on the exosomes, we first performed an exhaustive protein analysis of the vesicles. The proteins

found in the present study are reported in **Table 1**. Typical exosome markers, such as the transferring receptor, tetraspanins (CD63, CD81, CD82), and heat shock proteins, were detected (Table 1A), assessing the quality of the preparation. Exosomes were also characterized by their size and their electronegativity (supplemental Fig. II).

Regarding lipid-related proteins, we found a phospholipid scramblase, a protein that transports phospholipids between the two membrane leaflets, in both directions. The presence of this protein was consistent with the lack of membrane phospholipid asymmetry we reported earlier in RBL-derived exosomes (16). Also a member of the fatty acid binding proteins (E-FABP) was detected. FABPs constitute a multigene family of structurally homologous cytosolic proteins that bind and transport polyunsaturated fatty acids, such as arachidonic acid (AA) (31). Another type of protein was a prostaglandin F₂ receptor negative regulator, also called FPRP (32). FPRP associates with the PGF₂α receptor, thereby reducing ligand binding (33). However, the PGF₂ receptor was not found in exosomes, and the presence of the FPRP protein might be better related to its ability to form a tight complex with the tetraspan molecule CD81 (32).

Among the phospholipases, only phospholipase Cε hydrolyzing phosphoinositides was detected (Table 1B). Note that proteins known to interact with phospholipases D and A2 were present (Table 1C). Fructose biphosphate aldolase interacts directly with phospholipase D isoform PLD₂ and inhibits its activity (34). The exosomes contained casein kinase II (cK2) that can phosphorylate PLD₂ (35) and can also interact with sPLA₂-IIA (36), precisely one of the sPLA₂ isoforms we detected in the present work. Hsp 70, one of the typical exosome markers (Table 1A), has also been shown to interact with iPLA₂ (37).

Phospholipase Cε has been shown to be regulated by G proteins, either the subunits of heterotrimeric G proteins or monomeric GTPases (18), both being recovered in the exosomes (Table 1D). This prompted us to consider that GTPases could participate in the regulation of exosome lipolytic enzymes. Note that exosomes contained almost all members of the Ras superfamily GTPases [ARF, Rho, Rap, Rab, p21Ras, and Ran (Table 1D)] except Cdc42 (38). Possible pathways connecting the Ras superfamily GTPases and phospholipases have been reported. The GTPases RhoA and Arf 6 (Table 1D) are direct activators of PLD₂ (39, 40) from rat or human origin (41).

Exosomes contain the PLD/PAP pathway

Fig. 1A reports the presence of DG, PEt, and LPC when RBLwt exosomes were incubated with the fluorescent and membrane-diffusible phosphatidylcholine. We investigated whether an autonomous regulation of the lipolytic enzymes involved in the production of these lipid mediators could occur in exosomes. Addition of GTPγS up to 300 µM in RBLwt exosomes had no effect on the PLD activity (Fig. 1B, curve a). The activity was not increased by exosome sonication. Immunodetection showed the selective sorting of the PLD₂ isoform in exosomes (Fig. 1C, lane 2) compared with the parental cells, containing mainly

TABLE 1. Partial protein content of RBL-2H3wt exosomes

Protein Category	Accession Number	Protein Type	Observations
A) Exosome markers	Q62351	Transferrin receptor	
	P41731	CD63 antigen	Tetraspanin
	P40237	CD82 antigen	Tetraspanin
	P35762	CD81 antigen	Tetraspanin
	P11499	Heat-shock protein 90- β	
	P63017	Heat-shock cognate 70 kDa (Hsc70)	Interacts with phospholipase A2 (iPLA2)
B) Lipid-related proteins	Q8K4S1	Phosphoinositide-specific phospholipase C ϵ	Involved in phosphoinositide signaling
	Q9JJ00	Phospholipid scramblase	Mix phospholipids between membrane leaflets
	Q05816	Fatty acid binding protein (E-FABP)	Free fatty acid transporter
C) Phospholipase partners	Q5SRA8	Prostaglandin F2 receptor negative regulator	Interacts with CD81
	P05064	Fructose-bisphosphate aldolase	Interacts with phospholipase D (PLD2)
	P63017	Heat Shock protein 70 kDa	Interacts with phospholipase A2 (iPLA2)
	P67871	Casein kinase II β subunit	Interacts with phospholipase A2 (sPLA2)
D) GTP binding proteins	<i>Heterotrimeric</i>		
	P08752	G(i) α -2 subunit	
	P62874	G(i)G(s) β subunit 1	
	P62880	G(i)G(s) β subunit 2	
	<i>Monomeric GTPases</i>		
	P35278	Ras-related proretein Rab	
	Q9QUI0	Transforming protein RhoA	Interacts and activates phospholipase D (PLD2)
	P63835	Ras-related protein Rap-1A	
	Q61411	Transforming protein P21/H-Ras-1 (c-H-Ras)	
	Q61820	GTP-binding nuclear protein Ran	
P62331	ADP-ribosylation factor 6	Interacts and activates phospholipase D (PLD2)	
Q8BGX0	GTP-binding protein ARD-1 (ADP-ribosylation factor domain protein 1)		

Only proteins related to exosome markers, lipid metabolism, and G proteins are reported. The overall analysis identified 382 different proteins. Observations are detailed in the text.

PLD1 (Fig. 1C, lane 1). PLD₂ activation in RBLwt exosomes could be repressed by aldolase A, which was reported by the protein analysis (Table 1 [P05064] fructose bis-phosphate aldolase) and has been established as a direct inhibitor of PLD₂ by acting on its PH domain (34). Therefore, the occupation of the PH domain might prevent activation of the phospholipase.

We expected to modify the natural stoichiometry between the putative inhibitor aldolase A and PLD₂ by over-expressing the human HA-PLD₂ in RBL cells (supplemental Fig. II), the hHA-PLD₂ being targeted to exosomes (Fig. 1C, lanes 3, 4). Indeed, the basal PLD activity in RBLpld2 exosomes was twice as high as that of RBLwt exosomes (Fig. 1B; GTP γ S = 0). When increasing amounts of GTP γ S were added, a clear GTP dependency of the PLD activity in RBLpld2 exosomes was then observed (Fig. 1B, curve b). Phospholipase D activity generates the transphosphatidylated product PEt in the presence of ethanol (Fig. 1A), which competes with the water required to form PA. However, even in the absence of ethanol, PA was not detected across the chromatograms, suggesting the presence of a phosphatidate phosphatase (PAP1) on exosomes. When purified BODIPY-PA was injected into the HPLC system, the resulting peak exhibited a typical asymmetrical shape (Fig. 1D), which was not observed in any chromatograms obtained from exosome incubations with BODIPY-PC. Indeed, upon incubation of BODIPY-PA with exosomes, a

strong conversion into diglycerides was observed (Fig. 1E). Kinetics analysis demonstrated that 60% of the PA was hydrolyzed into diglycerides within 15 min (Fig. 1F), indicating the presence of a very active PAP1 in intact exosomes. The kinetics of PA hydrolysis were similar in the presence or absence of GTP γ S (Fig. 1F).

Exosomes from RBL cells carry GTP-activatable PLA₂ and contain the three classes of PLA₂

Fig. 1A reported the presence of PLA₂ activity as evidenced by the high LPC content. During the course of the studies on PLD activation (Fig. 1) we noticed a GTP-dependent enhancement of the LPC peak, both on RBLwt and RBLpld2 exosomes.

We then investigated whether a dynamic regulation of PLA₂ activity might occur in RBLwt exosomes (Fig. 2).

GTP γ S was able to reveal PLA₂ activity on intact exosomes incubated in calcium-free PBS and in the presence of the inhibitor MAFP (Fig. 2A). GTP γ S dose-dependent PLA₂ activation (Fig. 2B) fits a hyperbolic curve as shown by the linearity of the double-reciprocal plot (Fig. 2B, insert).

Exosomes exhibited a higher PLA₂ activity following sonication, indicating that the PLA₂ were partly located in the exosome lumen. The relative parts played by each PLA₂ class (cytosolic calcium-dependent cPLA₂, cytosolic calcium-independent iPLA₂, and secreted sPLA₂) were next investigated in the presence of GTP γ S on sonicated




Fig. 1. Exosomes contain the phospholipase D/ phosphatidate phosphatase pathway. **A:** Presence of phospholipase-mediated second messengers on exosomes. Exosomes from RBLwt cells were incubated for 1 h at 37°C with BODIPY-phosphatidylcholine (BODIPY-PC) as substrate. DG, diglycerides; PEt, phosphatidylethanol; PC, phosphatidylcholine; LPC, lysophosphatidylcholine. DG indicates the presence of a DG producing enzyme (phospholipase C or phosphatidate phosphatase); PEt was indicative of a phospholipase D activity, whereas LPC accounted for phospholipase A₂ activity. **B:** Comparative regulation by GTP γ S of PLD activity in RBLwt or RBLpld2 exosomes. Exosomes prepared from (a) RBLwt cells (●) or from (b) RBLpld2 cells (■) were incubated with BODIPY-PC for 1 h at 37°C in the presence of increasing concentrations of GTP γ S. Activity of PLD is expressed as pmol PET(phosphatidylethanol)/h/mg protein. Inset: Double-reciprocal plot: 1/(activity) versus 1/[GTP γ S]. **C:** The overexpressed human HA-PLD₂ is targeted to exosomes. Cell lysate and RBLpld2 exosome samples were blotted either with the anti-PLD antibody (N-PLD4; see “Materials”), recognizing both PLD1 and PLD₂ isoforms, or with the anti-HA antibody. **D:** Typical HPLC profile of BODIPY-labeled phosphatidic acid (BODIPY-PA) prepared from in vitro assay with phospholipase D (see “Methods”). The presence of positively charged triethylamine in the solvents delayed the elution of PA, leading to a characteristic asymmetrical peak. **E:** PA processing to yield diglyceride by RBLwt exosomes. Incubation of BODIPY-PA with exosomes proceeded for up to 1 h at 37°C, and then the products were separated as in Fig. 1D. **F:** Kinetics of PA hydrolysis. RBLwt exosomes were incubated with or without 100 μ M GTP γ S for various periods of time. The results are expressed as a percentage of the total products DG (○) + PA (●), with (solid lines) or without (dashed lines) GTP γ S.

exosomes. We observed that MAFP decreased the total PLA₂ activity by 60% (Fig. 2C). MAFP inhibits both cPLA₂ and, to a lesser extent, iPLA₂ (25). We next checked specific inhibitors. The specific cPLA₂ inhibitor (pyrrolidine-1) reduced total PLA₂ activity by 37% (Fig. 2C),

whereas bromoenolactone (BEL), the specific iPLA₂ inhibitor, abolished 39% of overall PLA₂ activity (Fig. 2C). The concentration of inhibitors was 50 μ M; i.e., above that used to inhibit the various PLA₂ in cells (24, 25). The sum of the inhibitions triggered by pyrrolidine-1 and BEL in




Fig. 2. Exosomes are carriers of GTP γ S-activatable phospholipases A₂. **A:** HPLC profiles of exosome phospholipase A₂ activity in the presence of GTP γ S. Intact RBLwt exosomes were preincubated with MAFP for 10 min at room temperature. The reaction was started by adding BODIPY-PC in the presence of GTP γ S at the indicated concentrations. Incubations were for 1 h at 37°C in Ca²⁺/Mg²⁺ free-PBS. **B:** Concentration-dependent effect of GTP γ S on exosome MAFP-insensitive PLA₂. Activity is expressed in pmol/h/mg of protein from HPLC profiles obtained in Fig. 2A. Inset: Double reciprocal plot: 1/(activity) versus 1/[GTP γ S]. **C:** Effect of class-specific PLA₂ inhibitors on total exosome PLA₂ activity. Sonicated exosomes from RBLwt cells were preincubated for 10 min at room temperature with 50 μ M of various class inhibitors—MAFP (cPLA₂ > iPLA₂ inhibitor), pyrrolidine (cPLA₂ inhibitor), BEL (iPLA₂ inhibitor), and Me-indoxam (sPLA₂ inhibitor)—in the presence of 100 μ M GTP γ S. The reaction was started by addition of BODIPY-PC. The respective inhibitions are expressed as percentages of the total activity measured without inhibitor. The sum of inhibitions triggered by pyrrolidine, BEL, and indoxam is indicated by the right bar (Total b-d). Results are means of four independent experiments \pm SEM for pyrrolidine, BEL and indoxam treatments, and six independent experiments \pm SEM for MAFP treatment. **E:** Immunodetection of PLA₂ class members in exosomes. The calcium-dependent cPLA₂-IVA, calcium-independent iPLA₂-VIA, and secreted sPLA₂-IIA and V were detected in RBLwt-derived exosomes by Western blotting. Exos = exosomes; sPLA₂ IIA = recombinant sPLA₂-IIA; sPLA₂ V = recombinant sPLA₂-V.




Fig. 3. Exosomes carry free fatty acids and arachidonic acid-derived bioactive lipids. A–D: Fatty acid distribution in exosomes. Details for analysis are reported in “Methods.” E: Prostaglandin content of exosomes and parent cells. Prostaglandins were quantified by GC-MS in untreated exosomes (Exos) or GTP γ S-treated exosomes (Exos +GTP) and in parent cells (Cells) (RBLwt). GTP γ S treatment was performed for 1 h at 37°C with 200 μ M of the nucleotide. 15d-PGJ₂ = 15-deoxy- $\Delta^{12,14}$ -PGJ₂. PGF₂ α , PGE₂, PGD₂ = prostaglandins F₂ α , E₂, and D₂

exosomes (Fig. 2C) led to the reduction of global PLA₂ activity by 76%, indicating that another type of PLA₂ activity was present. Me-indoxam, a specific inhibitor of secreted phospholipases (42) was checked, and it decreased total PLA₂ activity by 19% (Fig. 2C). Together, the cumulative effect of the three inhibitors diminished total PLA₂ activity by 95 ± 6.5%. The residual 5% activity might be related to PLA₂ insensitive to the inhibitors, such as some secreted sPLA₂ (43). Therefore, the three classes of PLA₂ contributed to the global PLA₂ activity detected in the exosomes.

We next assessed the presence of members of the three PLA₂ classes by using specific antibodies (Fig. 2D). cPLA₂-IVA was detected as a single band, whereas iPLA₂-VIA was present as processed forms (44). The iPLA₂-VIA can be cleaved at three different sites by caspase 3, which generates various processed forms depending upon the combination of the sites effectively cleaved (45). Fragmented forms of iPLA₂, similar to those we reported in Fig. 2D, were observed in erythrocyte-derived exosomes (44). Proteolytic processing has been shown to enhance the iPLA₂-VIA activity by removing part or complete ankyrin repeats suggested to function as a negative regulator (45). The form of 66 kDa we observed in Fig. 2D could correspond to the residual protein after caspase 3-mediated cleavage at the DVTD site of the iPLA₂, leading to the release of the first ankyrin repeat (45) and making likely that the iPLA₂-VIA is highly active in exosomes. Among the third class of PLA₂, namely, secreted sPLA₂, the presence of sPLA₂-IIA and sPLA₂-V groups was observed (Fig. 2D). Therefore, RBL exosomes concentrated members of each of the three classes of PLA₂ and are thus a unique cell compartment.

Exosomes as carriers of bioactive lipids

A large panel of free fatty acids was recovered from exosomes (Fig. 3A). Fatty acids could be carried from the parental cells or directly generated within the exosomes by the phospholipase A₂ activities. We previously established that 1 mg of exosome protein contained 230 nmoles phospholipid [see Ref. (16)]. Therefore 230 nmoles free fatty acid could be potentially released by the respective PLA₂ activities considering they displayed 100% efficiency, with an additional amount of free fatty acid originating from the lysophospholipase activity borne by cPLA₂ and iPLA₂. However, a total amount of 1,420 nmoles free fatty acid/mg exosome protein was measured (Fig. 3A), indicating that most of the exosome free fatty acid content was already present at the time of exosome membrane biogenesis. The chain length of the saturated fatty acids ranged from 14 to 24 carbons (Fig. 3B); the major ones were palmitic and stearic acids. Monounsaturated fatty acids were essentially from the omega-9 series (Fig. 3C); oleic acid was the most abundant. Polyunsaturated fatty acids almost exclusively contained members of the omega-6 series (Fig. 3D).

Only one member of the omega-3 series, namely, docosahexaenoic acid (DHA), was detected. Interestingly, AA accounted for about 30% of the total polyunsaturated fatty acids.

We next investigated whether bioactive lipids derived from AA could be found in exosomes. Quantification of prostaglandins was performed by GC-MS and demonstrated the presence of mainly PGE₂ and 15-deoxy-Δ^{12,14}-PGJ₂ [15d-PGJ₂] (Fig. 3E). The 15d-PGJ₂ was slightly enriched in the vesicles compared with the parent cells. The respective amounts of the various prostaglandins (PGF₂α, PGE₂, PGD₂, and 15d-PGJ₂) in exosomes was not enhanced by incubation with GTPγS (Fig. 3E), indicating that the prostaglandins originated either from the basal exosome PLA₂ activities or were loaded in the exosome membrane at the time of their biogenesis in parent cells. Note that COX-1 and COX-2 involved in the early steps of prostaglandin biosynthesis were expressed in exosomes (Fig. 3F), indicating that exosomes could be autonomous biological structures for the biosynthesis of the various prostaglandins. In that respect, the AA concentration in exosome membrane (45 nmoles/mg protein; Fig. 3D) was in excessive compared with the total membrane prostaglandin concentration (0.31 nmoles/mg protein; Fig. 3E).

The number of exosome vesicles per unit protein was established and used to calculate the amount of prostaglandin associated with a defined number of vesicles. Compared with the same number of parental cells, exosomes carried from 12 to 15 times more prostaglandins (Fig. 3G). To our knowledge, this is the first report of vesicle-associated release of prostaglandins from cells.

To evaluate the potential of exosomes as vehicles of bioactive lipids, we investigated whether exosomes could traffic between RBL-2H3 cells.

Exosomes are internalized by resting and activated RBL-2H3 cells and concentrate into endosomes

Confocal microscopy performed on living cells showed an accumulation of exosomes on the cell periphery detectable as soon as 5 min, with subsequent internalization leading to the formation of intracellular aggregates indicating storage in an endosomal compartment, as observed after 1 h and 4 h (Fig. 4A). Exosome uptake was an active process, as cross-linking of peripheral protein on target cells by paraformaldehyde impaired intracellular exosome accumulation (Fig. 4A, bottom panels). Only faint, diffuse cell labeling was observed in this case and was attributed to some exchange of the lipidic fluorescent probe between exosomes and the target cell during the step of exosome interaction with the peripheral cell membrane. We investigated whether activated cells, which release exosomes, were also able to internalize them. RBL-2H3 cells activated

respectively. F: Exosomes contain cyclooxygenases 1 and 2. Analysis of exosome cyclooxygenase expression by flow cytometry, compared to control isotype (gray shaded curves). G: Comparative prostaglandin content of exosomes and parent cells. Prostaglandin content per mg protein plotted in Fig. 3E was converted into cell-equivalents or vesicle (exosome)-equivalents, and normalized to 10⁶ cells or 10⁶ exosome vesicles, respectively. 1 mg protein corresponded to (71.4 ± 0.54) × 10⁵ cells and (5.96 ± 0.13) × 10⁵ exosome vesicles.




Fig. 4. Monitoring of exosome uptake by RBLwt cells A: Time-lapse monitoring of fluorescent (BODIPY-ceramide)-labeled exosome uptake by confocal microscopy. Uptake of exosomes labeled with BODIPY-ceramide (FITC-type probe) was monitored in a temperature-controlled CO₂ chamber with Zeiss LSM 510 software, and pictures were taken at the indicated times. Controls were performed by treating cells with paraformaldehyde (PFA) then washing prior to the addition of exosomes. Uptake was then recorded for 1–4 h (bottom panels). Bars = 5 µm. B: Time-lapse monitoring of fluorescent (BODIPY-ceramide)-labeled exosome by activated RBLwt cells following Fcε cross-linking. The cells were incubated overnight with IgE directed against DNP-HSA and Fcε cross-linking was triggered by adding DNP-HSA at the same time as fluorescent exosomes. Uptake was monitored as in Fig. 4A. Bars = 5µm. C: Time course of exosome internalization recorded by flow cytometry. Mean fluorescence of cells incubated with BODIPY-ceramide-labeled exosomes and plotted versus time. After each incubation time, noninternalized exosomes were washed away prior to FACS analysis. D: Quantification of exosome internalization. Fluorescent exosomes were incubated as function of time with resting cells. After washing at appropriate times, cell-associated fluorescence monitoring internalized exosomes was extracted with butanol and converted into µg exosome protein. Average of two determinations.

by Fcε-RI cross-linking appeared even more efficient at internalizing exosomes compared with resting ones (Fig. 4B).

Uptake was linear at least up to 1 h of incubation as shown by flow cytometry monitoring of exosome internalization (Fig. 4C). Similar data were obtained by measuring the BODIPY-ceramide content of target cells following organic extraction of the probe after exosome internalization. This procedure allowed us to quantify the amount of internalized exosomes. It was found that 1 µg of exosome was internalized in 1 h in 10⁶ resting cells (Fig. 4D).

Late endosomes in RBL-2H3 cells feature a dual function: being able to release their contents upon stimulation and being recipients of an endocytosis activity (46). We investigated whether exosomes could be colocalized with endosome markers following their incubation with target cells. Three markers were checked: (i) CD63, a general marker of late endosomes in RBL cells (47); (ii) the lysolipid lysobisphosphatidic acid (LBPA; also called BMP for bis[monoacylglycero]phosphate) that accumulates in MVB (21); i.e., late endosomes containing intraluminal

vesicles (see supplemental Fig. IIa); and (iii) Rh-PE, a fluorescent lipidic probe that accumulates specifically in late endosomes. **Fig. 5A–C** shows that exogenously added exosomes were labeled inside the cells by anti-CD63 antibody internalized by fluid-phase endocytosis. Localization of exosomes inside the endocytic track was more precisely investigated by monitoring the MVB distribution with anti-LBPA labeling (Fig. 5D–F). Remarkably, colocalization of exosomes was observed inside MVBs located close to the nucleus (Fig. 5F, white circles and arrows). With Rh-PE as the MVB-specific probe, supplementary evidence was obtained that exogenous exosomes joined the MVB compartment located close to the nucleus (Fig. 5G–I).

We estimated the concentration that could be reached by exosome-transported lipid mediators accumulated inside the endosomal compartment of a target cell. Considering an average diameter of 600 nm for an RBL-2H3 cell endosome (48), with an average number of 30 endosomes per RBL-2H3 cell (49), the resulting volume of the

entire endosomal compartment is about 500 times lower than the total cell volume (**Table 2**). Therefore exosome-transported lipid mediators accumulated inside endosomes (Figs. 4, 5) were 500 times more concentrated than if they were diluted in the whole cell volume (Table 2). As a consequence, the resulting PGJ₂ endosomal concentration reached 52 μM (Table 2). Other endosomal concentrations were 33 μM, 2.4 μM, and 1.7 μM for PGE₂, PGD₂, and PGF₂α respectively, whereas fatty acids, such as AA or DHA, reached millimolar concentrations (4 mM and 0.9 mM, respectively). Thus, target cell endosomes behave as a “concentrator compartment” of lipid mediators transported by exosomes, allowing micromolar concentrations of prostaglandins to be reached (i.e., concentrations able to trigger further biological responses, such as PGJ₂-mediated PPARγ activation). Note that the extent of exosome internalization by cells (1 μg exosomes/10⁶ cells/hr; Fig. 4D) was similar to the amount of exosomes released by 10⁶ cells upon stimulation (1.44 ±




Fig. 5. Characterization of the intracellular compartment accumulating exosomes. Antibodies against CD63 (late endosomes; LE) or LBPA (multivesicular bodies; MVB) and the MVB probe Rhodamine-PE (RhPE) were preinternalized in the cellular endocytic track. Cells were washed, and then fluorescent BODIPY-ceramide-labeled exosomes were pulsed for 4 h into cells. Excess exosomes were washed away and cells were fixed, permeabilized, and then CD63 or LBPA labeling was revealed by the appropriate secondary antibody. A–C: Endosome anti-CD63 labeling (A), exosome labeling (BODIPY-ceramide FITC) (B), and merge (C) showing the colocalization between exosomes and endosomes (orange and yellow spots represent different amounts of exosomes internalized). D–F: MVB anti-LBPA labeling (D), exosome labeling (BODIPY-ceramide FITC) (E), and merge (F) revealing various amounts of exosomes colocalized with MVBs (monitored by orange or yellow spots) occurring close to the nucleus (white circles and arrows). G–I: MVB Rhodamine-PE labeling (G), exosome labeling (BODIPY-ceramide FITC) (H), and merge (I) indicating different amounts of exosomes colocalizing with MVBs (monitored by orange or yellow spots) detected around the nucleus (white squares).

TABLE 2. Estimated concentration of exosome-transported PGJ₂ in endosomes of target cells

	A	B	C	D	E	F
	Mean diameter	Mean volume of 10 ⁶ cells or their endosomes	Exosomes internalized in 10 ⁶ cells in 1 h	PGJ ₂ transported by 1 μg exosomes	Final PGJ ₂ concentration in cells or endosomes	Concentration ratio
		<i>ml</i>	<i>μg</i>	<i>pmoles</i>	<i>μM</i>	
1) Exosomes			1	0.193		
2) Cell	15 μm	1.76 × 10 ⁻³			0.11	1
3) Endosomes	600 nm					
4) Total endosome compartment		3.38 × 10 ⁻⁶			57.1	519

The amount of PGJ₂ (column D) transported by the amount of exosomes plotted in column C was converted into μM concentrations (column E) either by considering the total volume of the recipient cells (column E line 2), or the total volume of late endosomes present in cells (column E line 4). The resulting values indicated that PGJ₂ was about 500 times more concentrated in the total endosome compartment than in the total cell volume (column F). Column A: Values were obtained from literature data (see "Results") and correspond to RBL-2H3 cells. Column B: The total volume of 10⁶ cells (line 2) and the corresponding volume of their endosome compartment (line 4) were calculated from data in column A (1 ml = 10¹² μm³). Column C: Net amount of exosome internalized in 10⁶ cells in 1 h (from Fig. 4D). Column D: Amount of PGJ₂ transported by the amount of exosome in column C; calculated from data in Fig. 3E [average of 193 pmol/mg protein in exosomes (Fig. 3E, right bars)]. Column E: PGJ₂ concentrations obtained by dividing the amount of PGJ₂ (column D) by the volume of cells (column B, line 2) or the volume of their total endosome compartment, considering an average of 30 endosomes per cell (column B, line 4). Column F: Ratio between PGJ₂ concentrations in endosomal compartment versus total cell. The same calculation procedure was applied to the other prostaglandins and two typical fatty acids [arachidonic acid (AA) and docosahexaenoic acid (DHA)] from data in Fig. 3 and reported in "Results."

^a 30 endosomes per cell.

0.47 μg), suggesting an efficient cell-to-cell communication process.

DISCUSSION

Exosomes are nanovesicles released from intact viable cells. They participate in cell-to-cell communication in various physiological and pathological situations, such as the immune response (50), inflammation (51), or atherogenesis (7). Mast cell-derived exosomes trigger functional maturation of dendritic cells (6). This maturation process involves secreted PLA₂ (13) and prostaglandins (14). Therefore, we investigated the presence of lipid-related proteins and lipid mediators on exosomes derived from the mast cell line RBL-2H3.

High-throughput protein analysis reported the presence of only four proteins related to lipid metabolism. However, we revealed the presence of other lipolytic proteins by their activity and by immunodetection. The presence of a high content in monomeric G proteins led us to hypothesize specific regulation of these phospholipases in exosomes. The subfamilies of Ras GTPases reported in Table 1 are cytosolic proteins likely to be located inside the exosomes. Therefore, GTP must cross the exosome membrane to activate GTPases and, subsequently, phospholipases. GTP transporters might be present in exosomes, as they have been reported in synaptic vesicles (52), a type of vesicle very similar to exosomes.

The difference in activation of the PLD by GTP between RBLpld2 and RBLwt exosomes appeared related to the stoichiometry between PLD₂ and aldolase A. Among the proteins recovered by protein analysis and reported in Table 1, aldolase (P05064) exhibited one of the highest

expression scores, whereas PLDs were not even detected by high-throughput analysis. Purified aldolase dose-dependently inhibits the PLD₂ activity (34); the inhibitor interaction occurs at the PH domain of PLD₂. This interaction might impair GTPases, such as RhoA or Arf6, to activate PLD₂, or it might prevent another domain of PLD₂, the phox homology domain (PX) that exhibits GAP activity, from activating GTPases (53).

Interaction domains on Arf 6 and RhoA with PLD₂ have been mapped (39, 40); however, no direct interaction between any of the small G proteins reported in the present study and PLA₂ have been reported so far. In whole cells, the cPLA₂ and the sPLA₂-IIA can be activated downstream of RhoA GTPases with subsequent effects on PGE₂ formation (54). Similarly, iPLA₂ activation downstream of RhoA has been suggested (55). However, in a cell-free system, such as exosomes, the signaling network between RhoA and the phospholipases might be different compared with whole cells, and exosomes might reveal a specific regulation of PLA₂ activities.

Regarding the functional role of exosome phospholipases A2, the calcium-independent iPLA₂ has been shown to allow the elimination of erythrocyte-derived exosomes by apoptotic cells (44). Concerning sPLA₂, exosomes transporting sPLA₂ IIA and V (Fig. 3) might account for the transcellular activity of these phospholipases reported to occur from activated RBL-2H3 cells (56). The group sPLA₂-V was reported to be secreted from RBL-2H3 cells and to trigger eicosanoid biosynthesis in neighboring target granulocytic cells (56). The sPLA₂-V activity appears related to IgE-dependent PGD₂ formation and to enhanced exocytosis in RBL-2H3 cells (57). Vesicular secretion of cPLA₂ has not been reported so far.




Fig. 6. Exosomes as intercellular signalosomes carrying GTP-activatable phospholipases and prostaglandins A: Exosomes carry GTP-activatable phospholipases. Proteins detected in RBLwt-derived exosomes related to phospholipase activation and reported in Table 1 were represented together with the phospholipases detected in the present work. Arrows indicate possible activation pathways based on literature data (see “Discussion”). Note the presence of lipid mediators in the exosome membrane. B: Exosomes as intercellular “signalosomes.” Exosomes released upon cell activation can traffic between resting cells (white) and activated cells (color). Exosomes could trigger autocrine and paracrine-type signals. C and D: Possible mechanism of exosome-mediated bioactive lipid delivery from endosomes in target cells. Inside the intracellular compartment accumulating exosomes in target cells (endosomes, Fig. 5), phospholipases borne by exosomes could participate upon activation by GTP in the fusion between exosomal and endosomal membranes, allowing delivery of exosome content into the cytosol. Exosomes carry prostaglandins, such as the PPAR γ agonist 15d-PGJ $_2$ (Fig. 3) and a FABP (Table 1) which can bind arachidonic acid (Fig. 3) and interact with PPAR γ (Fig. 6C). The 15d-PGJ $_2$ /PPAR γ and FABP/arachidonic acid/PPAR γ complexes would be further addressed to the nucleus (Fig. 6D).

The set of prostaglandins transported by exosomes (Fig. 3) are derived from PGH $_2$, and metabolic conversion of PGH $_2$ has been shown to occur through a transcellular mechanism between two different types of cells, containing either COX-1 and COX-2 or the terminal prostaglandin synthases (58, 59). Transporting from cell to cell metabolic precursors, such as PGD $_2$ (Fig. 3G), and en-

zymes, such as COX-1 and COX-2 (Fig. 3F), for the early steps of prostaglandin biosynthesis, exosomes could account for transcellular metabolism of prostanoids reported to occur between normal and tumor cells (59). Arachidonic acid present in exosomes (Fig. 3D) would serve as transcellular biosynthetic precursor. Although eicosanoid transcellular metabolism has been reported to occur at in-


inflammation sites between different cell types (60), one can conceive that RBL-derived exosomes are a mixed population bearing either the COX-1 and COX-2 or the terminal prostaglandin synthases; therefore, exosome exchange between RBL-2H3 cells would be required to complete the entire prostanoid biosynthesis pathway. In this respect, we showed earlier that RBL-2H3 cells release three distinct subpopulations of exosomes (23). The present work opens further investigations to understand the mechanisms underlying the transcellular metabolism of eicosanoids.

This transcellular metabolism requires exosome trafficking between cells. We have shown that exosomes added to target cells are rapidly internalized (Fig. 4) into the endocytic track and join the MVB network located close to the nucleus (Fig. 5). It is likely that the GTP-dependent activation of PLD and PLA₂ we observed in exosomes could occur inside the endocytic track of target cells. Many GTPases are present within the endocytosis track, some of them maintained in an active state even in unstimulated cells (61). GTP-activated phospholipases could participate in exosome fusion with the limiting membrane of the endosome, a process called “back-fusion” (62, 63). This process allows the lumen content of the exosomes to be released into the cytosol. Back-fusion molecular mechanisms require the lipid LBPA, whose biosynthesis involves a cPLA₂-type activity (64, 65), as well as a combination of PLA₂ and PLD activities (66). A previous report describes GTP-dependent cPLA₂-mediated fusion of secretory granules (67). Phosphatidic acid resulting from PLD activity is a fusogenic compound in presence of calcium (68). Diglycerides generated by the PI-PLC ϵ (Table 1) or the PLD/PA phosphatase pathway (Fig. 1) could participate in exosome-endosome fusion processes by lowering the surface pressure of the phospholipids (69). More DG can be expected in RBLpld2 exosomes and could account for the modification of the biophysical parameters (size and electronegativity) shown in supplemental Fig. II. In addition, phospholipid mixing between exosome and endosome membranes triggered by the scramblase we reported in Table 1 would facilitate membrane fusion.

We established in this work that exosomes transport prostaglandins from the parent cells. RBL-2H3 cells feature a mast cell phenotype, and eicosanoids play an essential role in mast cell physiology by regulating their function in host defense and disease (70). PGE₂ can block Fc ϵ RI-mediated exocytosis of mast cells (70). Exosomes, during at least the first 5–20 min (Fig. 5), provide a vehicle for PGE₂ to interact with its respective GPCRs on the periphery of target cells. Thereafter, exosome internalization provides the first mechanism described for 15deoxy $\Delta^{12,14}$ -PGJ₂ to enter the cells and possibly reach its intracellular targets. Actually, no specific peripheral receptors or mechanisms of entry have been identified to-date for this prostaglandin (17, 19). The exosome as a vehicle would allow the plasma membrane to be bypassed and 15d-PGJ₂ to accumulate in the endosomes of target cells, from where the prostaglandin would be released into the cytosol after fusion between exosome and endosome membranes. A possible mechanism is summarized in Fig. 6.

Exosomes could also supply the 15d-PGJ₂ already bound to its receptor, as a recent report indicates the presence of the PPAR γ receptor among proteins found in exosomes isolated from human serum (71). Interestingly, the exosome FABP we report in Table 1 could bind the AA present in exosomes (Fig. 3) and then interact directly with the PPAR γ receptor, the resulting FABP-AA-PPAR γ complex being subsequently addressed to the nucleus of target cells to regulate transcription (Fig. 6C) (72). In line with the possible modulation of nuclear receptors by exosome-carried mediators, note that PAPI, the diglyceride-generating enzyme we reported in Fig. 1, has recently been characterized as a transcriptional coactivator of the PPAR α receptor (73).

Further experiments are required to support the functional role of exosomes in RBL-2H3 cells. As a first step, we evaluated whether exosomes could carry sufficient amounts of the prostaglandin 15d-PGJ₂ to possibly trigger PPAR γ activation in target cells. When added to cells, 15d-PGJ₂ has been reported to trigger biological effects in the 10–40 μ M range (74). Exosome accumulation in endosomes were allowed to reach values > 50 μ M (Table 2); i.e., bioactive 15d-PGJ₂ concentrations.

Because of the dynamic regulation of their phospholipases by GTP, exosomes appear to behave as “signalosomes” (Fig. 6A). The “signalosomes” would circulate between cells and might regulate their functions whether cells are resting or activated (Fig. 6B). Stimulated RBL-2H3 cells feature enhanced endocytosis (46) and could internalize exosomes they had just released. Preliminary data we obtained indicate that exosomes inhibited Fc ϵ RI-mediated degranulation of RBL-2H3 cells. That this effect involves PGE₂, which is known to inhibit Fc ϵ RI-mediated exocytosis of mast cells (70), appears conceivable on the basis of data reported here. Also, by possibly providing 15d-PGJ₂ to PPAR γ of target cells, exosomes can repress the transcription of proinflammatory mRNAs (75). Circulating simultaneously with allergens that activate cells via Fc ϵ RI receptors, exosomes appear as a signaling device able to modulate the Fc ϵ RI-mediated mast cell response by means of phospholipases and lipid mediators that can be activated. 

The authors thank Justine Bertrand-Michel (Toulouse) and Michel Guichardant (Lyon) for lipidomics analysis; Bruno Payré for performing the transmission electronic microscopy; P.Winterton for correcting the English manuscript; and Dr. Toshihide Kobayashi (Riken Institute, Tokyo, Japan) for supplying the anti-LBPA antibody.

REFERENCES

1. Thery, C., S. Amigorena, G. Raposo, and A. Clayton. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr. Protoc. Cell Biol.* Chapter 3: Unit 3.22.
2. Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief, and H. J. Geuze. 1996. B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* **183**: 1161–1172.
3. Hess, C., S. Sadallah, A. Hefti, R. Landmann, and J. A. Schifferli. 1999. Exosomes released by human neutrophils are specialized functional units. *J. Immunol.* **163**: 4564–4573.

4. Werner, N., S. Wassmann, P. Ahlers, S. Kosiol, and G. Nickenig. 2006. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. *Arterioscler. Thromb. Vasc. Biol.* **26**: 112–116.
5. Valadi, H., K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee, and J. O. Lotvall. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **9**: 654–659.
6. Skokos, D., H. G. Botros, C. Demeure, J. Morin, R. Peronet, G. Birkenmeier, S. Boudaly, and S. Mecheri. 2003. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. *J. Immunol.* **170**: 3037–3045.
7. Zakharova, L., M. Svetlova, and A. F. Fomina. 2007. T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. *J. Cell. Physiol.* **212**: 174–181.
8. Miyayoshi, M., K. Tada, M. Koike, Y. Uchiyama, T. Kitamura, and S. Nagata. 2007. Identification of Tim4 as a phosphatidylserine receptor. *Nature.* **450**: 435–439.
9. Ristorcelli, E., E. Beraud, S. Mathieu, D. Lombardo, and A. Verine. 2009. Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. *Int. J. Cancer.* **125**: 1016–1026.
10. Alais, S., S. Simoes, D. Baas, S. Lehmann, G. Raposo, J. L. Darlix, and P. Leblanc. 2008. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. *Biol. Cell.* **100**: 603–615.
11. Schorey, J. S., and S. Bhatnagar. 2008. Exosome function: from tumor immunology to pathogen biology. *Traffic.* **9**: 871–881.
12. Sharples, R. A., L. J. Vella, R. M. Nisbet, R. Naylor, K. Perez, K. J. Barnham, C. L. Masters, and A. F. Hill. 2008. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. *FASEB J.* **22**: 1469–1478.
13. Perrin-Cocon, L., S. Agaoglu, F. Coutant, A. Masurel, S. Bezzine, G. Lambeau, P. Andre, and V. Lotteau. 2004. Secretory phospholipase A2 induces dendritic cell maturation. *Eur. J. Immunol.* **34**: 2293–2302.
14. Thurnher, M. 2007. Lipids in dendritic cell biology: messengers, effectors, and antigens. *J. Leukoc. Biol.* **81**: 154–160.
15. Laulagnier, K., C. Motta, S. Hamdi, S. Roy, F. Fauvelle, J. F. Pageaux, T. Kobayashi, J. P. Salles, B. Perret, C. Bonnerot, et al. 2004. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. *Biochem. J.* **380**: 161–171.
16. Laulagnier, K., D. Grand, A. Dujardin, S. Hamdi, H. Vincent-Schneider, D. Lankar, J. P. Salles, C. Bonnerot, B. Perret, and M. Record. 2004. PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes. *FEBS Lett.* **572**: 11–14.
17. Scher, J. U., and M. H. Pillinger. 2005. 15d-PGJ2: the anti-inflammatory prostaglandin? *Clin. Immunol.* **114**: 100–109.
18. Gandarillas, N. L., T. D. Bunney, M. B. Josephs, P. Gierschik, and M. Katan. 2009. In vitro reconstitution of activation of PLCepsilon by Ras and Rho GTPases. *Methods Mol. Biol.* **462**: 379–389.
19. Scher, J. U., and M. H. Pillinger. 2009. The anti-inflammatory effects of prostaglandins. *J. Investig. Med.* **57**: 703–708.
20. Rouault, M., C. Le Calvez, E. Boilard, F. Surrel, A. Singer, F. Ghomashchi, S. Bezzine, S. Scarzello, J. Bollinger, M. H. Gelb, et al. 2007. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. *Biochemistry.* **46**: 1647–1662.
21. Kobayashi, T., E. Stang, K. S. Fang, P. de Moerloose, R. G. Parton, and J. Gruenberg. 1998. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. *Nature.* **392**: 193–197.
22. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265–275.
23. Laulagnier, K., H. Vincent-Schneider, S. Hamdi, C. Subra, D. Lankar, and M. Record. 2005. Characterization of exosome subpopulations from RBL-2H3 cells using fluorescent lipids. *Blood Cells Mol. Dis.* **35**: 116–121.
24. Allal, C., C. Buisson-Brenac, V. Marion, C. Claudel-Renard, T. Faraut, P. Dal Monte, D. Streblov, M. Record, and J. L. Davignon. 2004. Human cytomegalovirus carries a cell-derived phospholipase A2 required for infectivity. *J. Virol.* **78**: 7717–7726.
25. Gubern, A., J. Casas, M. Barcelo-Torns, D. Barneda, X. de la Rosa, R. Masgrau, F. Picatoste, J. Balsinde, M. A. Balboa, and E. Claro. 2008. Group IVA phospholipase A2 is necessary for the biogenesis of lipid droplets. *J. Biol. Chem.* **283**: 27369–27382.
26. Gayral, S., P. Deleris, K. Laulagnier, M. Laffargue, J. P. Salles, B. Perret, M. Record, and M. Breton-Douillon. 2006. Selective activation of nuclear phospholipase D-1 by G protein-coupled receptor agonists in vascular smooth muscle cells. *Circ. Res.* **99**: 132–139.
27. Bouyssie, D., A. Gonzalez de Peredo, E. Mouton, R. Albigot, L. Roussel, N. Ortega, C. Cayrol, O. Burlet-Schiltz, J. P. Girard, and B. Monsarrat. 2007. Mascot file parsing and quantification (MFPaQ), a new software to parse, validate, and quantify proteomics data generated by ICAT and SILAC mass spectrometric analyses: application to the proteomics study of membrane proteins from primary human endothelial cells. *Mol. Cell. Proteomics.* **6**: 1621–1637.
28. Blich, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**: 911–917.
29. Payre, B., P. de Medina, N. Boubekur, L. Mhamdi, J. Bertrand-Michel, F. Terce, I. Fourquaux, D. Goudouneche, M. Record, M. Poirot, et al. 2008. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. *Mol. Cancer Ther.* **7**: 3707–3718.
30. Soares, A. F., O. Nosjean, D. Cozzone, D. D’Orazio, M. Becchi, M. Guichardant, G. Ferry, J. A. Boutin, M. Lagarde, and A. Geloën. 2005. Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. *Biochem. Biophys. Res. Commun.* **337**: 521–525.
31. Kitanaka, N., Y. Owada, R. Okuyama, H. Sakagami, M. R. Nourani, S. Aiba, H. Furukawa, M. Watanabe, M. Ono, T. Ohteki, et al. 2006. Epidermal-type fatty acid binding protein as a negative regulator of IL-12 production in dendritic cells. *Biochem. Biophys. Res. Commun.* **345**: 459–466.
32. Stipp, C. S., D. Orlicky, and M. E. Hemler. 2001. FPRP, a major, highly stoichiometric, highly specific CD81- and CD9-associated protein. *J. Biol. Chem.* **276**: 4853–4862.
33. Orlicky, D. J., R. Berry, and J. M. Sikela. 1996. Human chromosome 1 localization of the gene for a prostaglandin F2alpha receptor negative regulatory protein. *Hum. Genet.* **97**: 655–658.
34. Kim, J. H., S. Lee, T. G. Lee, M. Hirata, P. G. Suh, and S. H. Ryu. 2002. Phospholipase D2 directly interacts with aldolase via its PH domain. *Biochemistry.* **41**: 3414–3421.
35. Ganley, I. G., S. J. Walker, M. Manifava, D. Li, H. A. Brown, and N. T. Kistakis. 2001. Interaction of phospholipase D1 with a casein kinase-2-like serine kinase. *Biochem. J.* **354**: 369–378.
36. Shimoyama, Y., R. Sakamoto, T. Akaboshi, M. Tanaka, and K. Ohtsuki. 2001. Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro. *Biol. Pharm. Bull.* **24**: 1004–1008.
37. Mancuso, D. J., C. M. Jenkins, and R. W. Gross. 2000. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). *J. Biol. Chem.* **275**: 9937–9945.
38. Konstantinopoulos, P. A., M. V. Karamouzis, and A. G. Papavassiliou. 2007. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. *Nat. Rev. Drug Discov.* **6**: 541–555.
39. Bae, C. D., D. S. Min, I. N. Fleming, and J. H. Exton. 1998. Determination of interaction sites on the small G protein RhoA for phospholipase D. *J. Biol. Chem.* **273**: 11596–11604.
40. Hiroyama, M., and J. H. Exton. 2005. Localization and regulation of phospholipase D2 by ARF6. *J. Cell. Biochem.* **95**: 149–164.
41. Le Stunff, H., L. Dokhac, S. Bourgoïn, M. F. Bader, and S. Harbon. 2000. Phospholipase D in rat myometrium: occurrence of a membrane-bound ARF6 (ADP-ribosylation factor 6)-regulated activity controlled by betagamma subunits of heterotrimeric G-proteins. *Biochem. J.* **352**: 491–499.
42. Lambeau, G., and M. H. Gelb. 2008. Biochemistry and physiology of mammalian secreted phospholipases A2. *Annu. Rev. Biochem.* **77**: 495–520.
43. Singer, A. G., F. Ghomashchi, C. Le Calvez, J. Bollinger, S. Bezzine, M. Rouault, M. Sadilek, E. Nguyen, M. Lazdunski, G. Lambeau, et al. 2002. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. *J. Biol. Chem.* **277**: 48535–48549.
44. Blanc, L., C. Barres, P. Bette-Bobillo, and M. Vidal. 2007. Reticulocyte-secreted exosomes bind natural IgM antibodies: involvement of a ROS-activatable endosomal phospholipase iPLA2. *Blood.* **110**: 3407–3416.

45. Lauber, K., E. Bohn, S. M. Krober, Y. J. Xiao, S. G. Blumenthal, R. K. Lindemann, P. Marini, C. Wiedig, A. Zobywalski, S. Baksh, et al. 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. *Cell*. **113**: 717–730.
46. Barbu, A. E., and I. Pecht. 2005. Desensitization of mast cells' secretory response to an immuno-receptor stimulus. *Immunol. Lett.* **100**: 78–87.
47. Amano, T., T. Furuno, N. Hirashima, N. Ohyama, and M. Nakanishi. 2001. Dynamics of intracellular granules with CD63-GFP in rat basophilic leukemia cells. *J Biochem.* **129**: 739–744.
48. Grimberg, E., Z. Peng, I. Hammel, and R. Sagi-Eisenberg. 2003. Synaptotagmin III is a critical factor for the formation of the perinuclear endocytic recycling compartment and determination of secretory granules size. *J. Cell Sci.* **116**: 145–154.
49. Tadokoro, S., T. Kurimoto, M. Nakanishi, and N. Hirashima. 2007. Munc18-2 regulates exocytotic membrane fusion positively interacting with syntaxin-3 in RBL-2H3 cells. *Mol. Immunol.* **44**: 3427–3433.
50. Simons, M., and G. Raposo. 2009. Exosomes—vesicular carriers for intercellular communication. *Curr. Opin. Cell Biol.* **21**: 575–581.
51. Bhatnagar, S., K. Shinagawa, F. J. Castellino, and J. S. Schorey. 2007. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. *Blood*. **110**: 3234–3244.
52. Santos, T. G., D. O. Souza, and C. I. Tasca. 2006. GTP uptake into rat brain synaptic vesicles. *Brain Res.* **1070**: 71–76.
53. Lee, C. S., I. S. Kim, J. B. Park, M. N. Lee, H. Y. Lee, P. G. Suh, and S. H. Ryu. 2006. The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis. *Nat. Cell Biol.* **8**: 477–484.
54. Petty, C., G. Fritz, J. Pfeilschifter, and A. Huwiler. 2004. Inhibition of Rho modulates cytokine-induced prostaglandin E2 formation in renal mesangial cells. *Biochim. Biophys. Acta.* **1636**: 108–118.
55. Maeda, A., Y. Ozaki, S. Sivakumaran, T. Akiyama, H. Urakubo, A. Usami, M. Sato, K. Kaibuchi, and S. Kuroda. 2006. Ca²⁺-independent phospholipase A2-dependent sustained Rho-kinase activation exhibits all-or-none response. *Genes Cells.* **11**: 1071–1083.
56. Wijewickrama, G. T., J. H. Kim, Y. J. Kim, A. Abraham, Y. Oh, B. Ananthanarayanan, M. Kwatia, S. J. Ackerman, and W. Cho. 2006. Systematic evaluation of transcellular activities of secretory phospholipases A2. High activity of group V phospholipases A2 to induce eicosanoid biosynthesis in neighboring inflammatory cells. *J. Biol. Chem.* **281**: 10935–10944.
57. Sawada, H., M. Murakami, A. Enomoto, S. Shimbara, and I. Kudo. 1999. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. *Eur. J. Biochem.* **263**: 826–835.
58. Salvado, M. D., A. Alfranca, A. Escolano, J. Z. Haeggstrom, and J. M. Redondo. 2009. COX-2 limits prostanoid production in activated HUVECs and is a source of PGH2 for transcellular metabolism to PGE2 by tumor cells. *Arterioscler. Thromb. Vasc. Biol.* **29**: 1131–1137.
59. Folco, G., and R. C. Murphy. 2006. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. *Pharmacol. Rev.* **58**: 375–388.
60. Zarini, S., M. A. Gijon, A. E. Ransome, R. C. Murphy, and A. Sala. 2009. Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. *Proc. Natl. Acad. Sci. USA.* **106**: 8296–8301.
61. Kondo, H., R. Shirakawa, T. Higashi, M. Kawato, M. Fukuda, T. Kita, and H. Horiuchi. 2006. Constitutive GDP/GTP exchange and secretion-dependent GTP hydrolysis activity for Rab27 in platelets. *J. Biol. Chem.* **281**: 28657–28665.
62. van der Goot, F. G., and J. Gruenberg. 2006. Intra-endosomal membrane traffic. *Trends Cell Biol.* **16**: 514–521.
63. Falguieres, T., P. P. Luyet, and J. Gruenberg. 2009. Molecular assemblies and membrane domains in multivesicular endosome dynamics. *Exp. Cell Res.* **315**: 1567–1573.
64. Shinozaki, K., and M. Waite. 1999. A novel phosphatidylglycerol-selective phospholipase A2 from macrophages. *Biochemistry.* **38**: 1669–1675.
65. Hullin-Matsuda, F., K. Kawasaki, I. Delton-Vandenbroucke, Y. Xu, M. Nishijima, M. Lagarde, M. Schlame, and T. Kobayashi. 2007. De novo biosynthesis of the late endosome lipid, bis(monoacylglycero) phosphate. *J. Lipid Res.* **48**: 1997–2008.
66. van Blitterswijk, W. J., and H. Hilkmann. 1993. Rapid attenuation of receptor-induced diacylglycerol and phosphatidic acid by phospholipase D-mediated transphosphatidylation: formation of bisphosphatidic acid. *EMBO J.* **12**: 2655–2662.
67. Sattar, A. A., and R. Haque. 2007. Cytosolic PLA2 in zymogen granule fusion and amylase release: inhibition of GTP-induced fusion by arachidonyl trifluoromethyl ketone points to cPLA2 in G-protein-mediated secretory vesicle fusion. *J Biochem.* **141**: 77–84.
68. Blackwood, R. A., J. E. Smolen, A. Transue, R. J. Hessler, D. M. Harsh, R. C. Brower, and S. French. 1997. Phospholipase D activity facilitates Ca²⁺-induced aggregation and fusion of complex liposomes. *Am. J. Physiol.* **272**: C1279–C1285.
69. van Rossum, D. B., D. Oberdick, Y. Rbaibi, G. Bhardwaj, R. K. Barrow, N. Nikolaidis, S. H. Snyder, K. Kiselyov, and R. L. Patterson. 2008. TRP_2, a lipid/trafficking domain that mediates diacylglycerol-induced vesicle fusion. *J. Biol. Chem.* **283**: 34384–34392.
70. Boyce, J. A. 2007. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. *Immunol. Rev.* **217**: 168–185.
71. Looze, C., D. Yui, L. Leung, M. Ingham, M. Kaler, X. Yao, W. W. Wu, R. F. Shen, M. P. Daniels, and S. J. Levine. 2009. Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein. *Biochem. Biophys. Res. Commun.* **378**: 433–438.
72. Tan, N. S., N. S. Shaw, N. Vinckenbosch, P. Liu, R. Yasmin, B. Desvergne, W. Wahli, and N. Noy. 2002. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. *Mol. Cell. Biol.* **22**: 5114–5127.
73. Reue, K., and D. N. Brindley. 2008. Thematic Review Series: Glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. *J. Lipid Res.* **49**: 2493–2503.
74. Cerbone, A., C. Toaldo, S. Laurora, F. Briatore, S. Pizzimenti, M. U. Dianzani, C. Ferretti, and G. Barrera. 2007. 4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. *Free Radic. Biol. Med.* **42**: 1661–1670.
75. Szanto, A., and L. Nagy. 2008. The many faces of PPARgamma: anti-inflammatory by any means? *Immunobiology.* **213**: 789–803.